The Antidote: Inside the World of New Pharma (82 page)

Procrit,
208

products, productivity,
1
,
5
,
14
,
23
,
28
,
45
,
71
,
84
–85,
87
,
100
,
122
–23,
195
,
204
,
225
,
243
,
247
,
261
,
284
,
300
,
310
,
314
,
329
,
340
,
366
,
378
,
385

in future,
387
–88

gradualism in,
4
,
6
–7

HCV and,
34
,
194
,
203
,
213
,
231
,
239
–40,
332
–33

Vertex-Novartis partnership and,
57
,
59

Vertex’s earnings calls and,
307
–8,
362

ProEd Regulatory,
227
–28,
240
,
243
,
255
,
265

profits, profitability,
27
,
42
,
44
–47,
52
,
83
–85,
87
,
146
,
189
,
225
,
250
–51,
281
,
309
–10,
312
,
332
,
376
,
388

and grand contradiction in pharmaceutical industry,
246
–47

HCV and,
44
,
83
,
94
,
238
,
339
,
342

Merck on,
98
,
152
,
279

of pharmaceutical companies,
2
–6

succession and,
198
,
361

Vertex’s earnings calls and,
339
–40,
362

Vertex’s portfolio process and,
97
–98

World War II and,
151
–52

pronase,
126

Propecia,
46

Proscar,
15
,
46

prostates,
15
,
46
,
311

proteases, protease inhibitors,
13
–20,
53
,
315

active protein research and,
16
–18

HCV and,
22
–23,
32
–35,
37
–38,
40
,
44
,
49
,
61
–62,
76
–77,
82
–83,
91
,
93
–95,
101
,
105
,
128
,
131
,
140
,
148
,
151
,
158
,
172
,
176
,
220
,
276
,
289
,
336

HIV and,
13
–15,
17
–20,
24
–32,
35
–36,
46
,
50
,
76
–77,
82
,
147
–48,
183
,
220
,
230
,
242
,
357

ICE and,
23
,
30

patents and,
30
–32,
35
–36

structures of,
15
–19,
23
,
33
–34,
37
–38,
40

sulfonamides and,
32
,
35

Vertex-Glaxo partnership and,
85
,
87

Vertex’s preclinical experiments on,
24
–25

see also specific molecules

proteins,
32
,
43
,
71
,
89
,
113
–14,
192
,
201
,
205

CF and,
67
–69,
79
–81,
119
–20,
179
,
252
,
364

HCV and,
22
,
33
–34,
36
–39,
48
,
63
,
94
–95,
220

ICE and,
29
–30

kinases and,
53
–56

ultrapure, active,
16
–18,
20
,
36
,
252

Provenge,
311

Prozac,
315
–16

pseudomonas,
80
,
255

PSI-7977,
327
,
329
,
347
–49,
356
,
363

psoriasis,
93
,
99
–100,
177
,
260

p38 mitogen-activated protein (MAP) kinase,
53
–56,
92
,
128
,
146
,
177

halting study on,
72
–75

VX-745 and,
53
,
55
–56,
71
–75,
87
,
92
,
277

pyrazinamide (PZA),
269
–70

rashes,
171
–72,
248

Incivek and,
151
,
171
,
182
–83,
186
,
257
,
268
–71,
273
,
275
,
287
,
344
,
347
,
378

Read, Ian,
246

real option valuation (ROV) models,
92
–93,
95
,
101

Reesink, Henk,
131
,
136
–37

Regulation Fair Disclosure (Reg FD),
175
,
210
,
303
,
309
,
328
–29

replicon system,
105

research and development (R&D),
2
–7,
11
–18,
45
,
65
–66,
77
,
80
,
88
–92,
114
,
122
–23,
138
,
145
,
149
,
163
–64,
183
–85,
195
,
207
–8,
210
,
245
–47,
259
–61,
272
,
281
,
300
,
316
,
323
,
333
–34,
340
,
361
,
375
,
386
–87

and active protein,
16
–18,
36
,
352

and CF,
68
,
70
,
120
,
127
,
343

and East Asian prospects,
174
,
327

Emmens on,
261
,
310

failure rates in,
6
,
13
–16

and HCV,
44
,
48
,
230
,
238
,
356

in history,
3
–5

and kinases,
55
,
58
,
72

and layoffs at Vertex,
89
–90

and Mueller’s reorganizing,
334
,
336

overextended at Vertex,
88
–89

on stem cells,
70
,
204
–5,
322

and values,
325
,
357

and Vertex-Novartis partnership,
58
,
107

and Vertex’s culture,
290
,
376

and Vertex’s earnings calls,
308
,
362

response-guided therapy (RGT),
266
–67,
282

restraint-of-trade cases,
6

Reuters,
197
,
288
,
332
,
361
,
363

reverse transcriptase,
20
,
148

rheumatoid arthritis (RA),
68
,
314

ICE and,
23
,
52
,
77
–78,
85
,
92
–93

kinases and,
53
–55,
177
,
215
,
317
–18,
380

of Lindbergh,
154

VX-509 and,
317
–18

VX-745 and,
71
–72,
75

ribavirin:

HCV and,
61
,
129
,
135
,
138
–39,
148
,
155
,
165
–67,
171
–72,
208
,
220
–22,
229
,
257
,
262
,
266
,
274
–75,
320
,
327
,
347
–48,
358
,
362
–63

Victrelis and,
283
–84,
299

ribonucleic acid (RNA):

HCV and,
63
,
82
,
130
,
137
,
147
,
266

HIV and,
20
,
147
–48

Rice, Charles,
22
–23,
32
,
34
–35,
37
,
40
,
105
,
232

Richards, Alfred Newton,
152

Richie, Lionel,
324

Roche,
19
,
36
,
101
,
224
,
230

Genentech acquired by,
185
,
188
,
200
,
243

HCV and,
22
,
34
,
42
,
61
,
82
,
165
–66,
213
,
220
,
284
,
342
,
347
–48,
357

Merck’s partnership with,
284
,
287
–88

Roussel-Uclaf,
47
,
51

Sachdev, Amit,
243
,
322
,
351
,
370

HCV and,
163
–67,
203
,
213
–14,
265
,
300
,
350
,
373
–74

sales, selling, salespeople,
6
–7,
12
,
24
,
52
,
96
,
115
,
136
,
148
,
166
,
186
–87,
195
–97,
218
–19,
230
,
245
–47,
261
,
281
–85,
317
,
351
,
385

CF and,
250
,
301
,
327
,
343
–44,
353

Cumbo’s recruitment of,
224
–26,
228
,
241
–42,
376
,
379

Emmens’s background and,
123
,
210

HCV and,
44
,
83
,
149
,
301
,
333
,
375
,
379

Incivek and,
212
–13,
222
,
224
–26,
238
,
241
–42,
247
,
277
,
282
–85,
299
,
303
,
307
–8,
314
–16,
325
,
327
–32,
339
–42,
347
–48,
350
,
356
–57,
362
,
372
–73,
375
–76,
379

Kalydeco and,
250
,
343
–44,
353
,
386

Merck and,
277
,
284
–85,
307
,
311

Vertex’s earnings calls and,
307
–9,
339
–41,
362

Vertex’s portfolio process and,
97
–98

Victrelis and,
277
,
284
–85,
288
,
299
,
307
,
315
–16,
342

see also marketing

Sanders, Charles,
267
–68,
273

Genentech takeover and,
185
,
188

succession and,
143
–44,
146
,
188
–89

Sarepta Therapeutics,
377
,
379

Sato, Vicki,
27
,
45
,
56
,
71
,
73
,
87
,
89
,
115
,
122

CF and,
68
–69,
80
,
127
,
141

on fear and fun,
110
,
117
,
127

HCV and,
21
,
23
,
39
–41,
64
,
82
–83,
93
–94,
107
–8,
110
–11,
127
,
232

HIV and,
18
–20,
25
–26,
31
,
51
,
91
,
94

investor day and,
101
–2

Kwong’s recruitment and,
41
–42

lawsuit against,
75
,
127
–28

portfolio process and,
90
,
92
–93,
98

retirement of,
127
–28,
132
,
141
,
184

Smith’s relationship with,
280
–81

Vertex-Novartis partnership and,
57
,
59
,
107

and Vertex’s acquisition of Aurora,
67
,
78

Vertex’s reorganization and,
59
–60,
64
–65

VX-745 and,
72
,
74
–75

Washington retroviral conference and,
25
–26

“Save the Planet” (Boger),
203
–4

Schapiro, Mary,
369
–70

Schering-Plough Corporation,
49
,
101
,
343

HCV and,
39
–40,
42
,
44
,
61
,
82
,
131
,
140
,
150
–51,
165
–66,
172
,
186
,
194
,
208
,
213
,
217
–18,
229
–30,
245
,
260
,
266
,
284